Strategic Partnerships Leverage Arcturus ongoing collaborations with CSL Seqirus, BARDA, and the Japan JV ARCALIS to explore co-development, manufacturing, or distribution opportunities for mRNA vaccines and therapeutics in liver and respiratory rare diseases.

Product Pipeline Target near-term and mid-term care opportunities around ARCT-810 for OTC deficiency and other liver conditions, and ARCT-154 saRNA COVID vaccine variants, aligning outreach to specialty clinics and hospital systems focusing on rare diseases and immunization programs.

Manufacturing Reach Capitalize on Arcturus’ mRNA drug substance and manufacturing expertise to propose contract manufacturing, fill-finish, or process optimization partnerships for biotech firms seeking scalable mRNA production solutions.

Investor Messaging Position Arcturus as a growth partner in advanced RNA platforms (LUNAR delivery, saRNA, and diverse nucleic acid therapies) to potential customers and strategic investors seeking differentiated, patented delivery technologies and robust IP coverage.

Academic & Regulatory Engage academic and regulatory stakeholders around the Harvard-led study on saRNA immune responses to boost credibility, identify co-funding, and explore joint research opportunities that may shorten time-to-clinical milestones for partner programs.